Xiao Liang

Xiao Liang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2026 in Molecular Biomedicine
Verified
Journal Article
Open access
PDF file
JZJiamin Zhu
Jiamin Zhu
LLLiting Lv
Liting Lv
YYYuqian Yan
Yuqian Yan
SWSimin Wang
Simin Wang
XLXiangdong Lu
Xiangdong Lu
XLXiao Liang
Xiao Liang
Autophagy represents a conserved lysosome-dependent catabolic mechanism that safeguards cellular energetic homeostasis and supports adaptive metabolic remodeling under diverse stress conditions. In cancer, autophagy displays a highly context-dependent “double-edged sword” behavior. During the early stages of tumorigenesis, autophagy can suppress malignant transformation by preserving genomic stability, restraining chronic inflammation, and limiting the acquisition of malignant stemness, thereby helping preserve cellular integrity in early tumorigenesis. However, as tumors progress, autophagy can be reprogrammed into an adaptive survival mechanism that supplies tumor growth, metastatic dissemination, and resistance to multiple therapeutic modalities in response to hypoxia, nutrient deprivation, and therapeutic stress. Within the framework of tumor evolution, this review systematically integrates the molecular mechanisms and regulatory networks underlying different forms of autophagy, including canonical, non-canonical, and selective forms. We explore how autophagy intersects with metabolic reprogramming, immune signaling, DNA damage responses, and regulated cell death, and discuss its involvement in tumor progression, microenvironment remodeling, metastasis, and therapy resistance, with relevance to interactions between tumor cells and the surrounding microenvironment. We also summarize recent developments in autophagy-targeted approaches, including chloroquine derivatives, emerging small-molecule inhibitors, and natural compounds, and consider the challenges that remain for clinical translation, especially those related to context-dependent effects and therapeutic application. Collectively, this review provides an updated understanding of autophagy in tumor evolution and informs future mechanistic and therapeutic investigations.

17 March 2026 in Journal of Proteome Research
Verified
Journal Article
Closed access
XLXiao Liang
Xiao Liang
YLYilin Liu
Yilin Liu
XMXiaoting Ma
Xiaoting Ma
SJShuang Jiang
Shuang Jiang
ZSZhenjiang Sun
Zhenjiang Sun
XLXiao Liang
Xiao Liang

6 July 2026 in Human Mutation
Verified
Journal Article
Open access
HSHongyu Shen
Hongyu Shen
JLJinbo Lu
Jinbo Lu
QYQi Yan
Qi Yan
JCJinjiang Chou
Jinjiang Chou
XLXiao Liang
Xiao Liang
LFLei Fan
Lei Fan
Diffuse large B-cell lymphoma (DLBCL) is characterized by profound heterogeneity that underpins varied clinical outcomes. To decipher this complexity, we performed an integrated single-cell and genomic analysis. Using scRNA-seq data (GSE182434), we identified six distinct malignant B-cell subclusters (MB1-MB6) within the DLBCL ecosystem. Cell-cell communication analysis revealed intricate interaction networks, particularly involving the MIF and Complement pathways. Prognostic analysis of bulk transcriptomic data (GSE32918) identified the MB5-related gene signature as the most critical factor associated with poor overall survival. This MB5 subgroup was associated with enhanced proliferative processes, a higher tumor mutational burden, and specific comutations. Leveraging MB5 marker genes, we developed and validated a robust CoxBoost-RSF machine-learning model that effectively stratified patient risk in independent cohorts. Our study defines the MB5 malignant B-cell subgroup as a key driver of DLBCL aggressiveness and provides both a novel prognostic biomarker and a framework for personalized therapeutic targeting.